{"id":5514,"date":"2022-02-21T20:27:54","date_gmt":"2022-02-21T19:27:54","guid":{"rendered":"https:\/\/nanexa.com\/?page_id=5514"},"modified":"2022-05-19T10:27:09","modified_gmt":"2022-05-19T08:27:09","slug":"nex-18","status":"publish","type":"page","link":"https:\/\/nanexa.com\/sv\/nex-18\/","title":{"rendered":"NEX-18"},"content":{"rendered":"\n
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t\t\n\n

nex 18<\/span> F\u00d6R
BEHANDLING AV mDS (MYELODYSPLASTIC SYNDROME)<\/span><\/h1>\n\n\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
  1. Vad \u00e4r MDS?<\/a><\/li>
  2. NEX-18: Fr\u00e5n en injektion per dag i sju dagar till en injektion i m\u00e5naden<\/a><\/li>
  3. NEX-18: Minska den initiala fris\u00e4ttningen<\/a><\/li>\t\t\t\t<\/ol>\t\t\t<\/div>\n\t\t<\/div>\n\t\t
    \n\t\t\t\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n
    <\/div>

    Vad \u00e4r<\/p><\/div>

    \n\n
    \n
    \n

    VAD \u00c4R MDS?<\/span><\/h2>\n\n\n\n

    Myelodysplastiskt syndrom (MDS) \u00e4r en grupp aggressiva och l\u00e5ngvariga blodcancersjukdomar. De orsakar ett brett spektrum av ytterst p\u00e5frestande symtom, fr\u00e5n illam\u00e5ende, yrsel och andn\u00f6d till bl\u00f6dningar och \u00e5terkommande infektioner.<\/h3>\n\n\n\n

    Fyrtio procent av alla MDS-patienter anses vara utsatta f\u00f6r h\u00f6g eller mycket h\u00f6g risk, med en \u00f6verlevnadsprognos p\u00e5 cirka 2 \u00e5r (1)<\/sup>. MDS kallas ofta \u201dpre-leukemi\u201d eftersom en tredjedel av patienterna s\u00e5 sm\u00e5ningom utvecklar akut myeloisk leukemi (AML).<\/p>\n<\/div>\n\n\n\n

    \n
    \n\t\t\n\t
    \n\n

    Median\u00e5lder vid diagnos \u00e4r 76 \u00e5r
    Majoriteten av patienterna \u00e4r \u00f6ver 65 \u00e5r
    Endast 6% av patienterna \u00e4r under 50 \u00e5r (2)<\/sup><\/p>\n\n<\/div>\n\t<\/div>\n\n\n<\/div>\n<\/div>\n\n\n\n

    <\/div>\n\n\n\n
    \n
    \n

    F\u00d6REKOMST<\/span>
    MDS f\u00f6rekommer fr\u00e4mst hos \u00e4ldre. Sjukdomen \u00f6kar i takt med att andelen \u00e4ldre m\u00e4nniskor \u00f6kar, samtidigt som behandlingsresultatet under de senaste decennierna sakta har f\u00f6rb\u00e4ttrats (3)<\/sup>. 2020 insjuknade  250 000 patienter globalt, en siffra som sp\u00e5s \u00f6ka till 310 000 patienter \u00e5r 2028 (4)<\/sup>.<\/p>\n<\/div>\n\n\n\n

    \n
    \n\t
    \n\t\t\t\t\t

    Antal nyinsjuknande
    i MDS globalt<\/p>\n\t\t\t\t\t<\/div>\n\t\t

    \n\t\t\t\n\t\t\t
    \n\t\t\t\t\t\t\t\t
    \u00c5R<\/div>\n\t\t\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t

    Afrika<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Europa<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Nordamerika<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

    \n\t\t\t\t\t
    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Asien<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Latinamerika och V\u00e4stindien<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t

    \n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\n\n\t\t\t\t\t\t<\/svg>\n\t\t\t\t\t\t\t\t\t\t\t\t

    Oceanien<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<\/div>\n<\/div>\n\n\n\n

    AZACITIDIN: GRUNDBEHANDLING F\u00d6R MDS SOM \u00c4R ANSTR\u00c4NGANDE B\u00c5DE F\u00d6R PATIENTEN OCH V\u00c5RDEN<\/span><\/p>\n\n\n\n

    Vid MDS \u00e4r f\u00f6rsta linjens behandling azacitidin (produktnamn: Vidaza\u00ae)\u00a0som administreras med\u00a0subkutana injektioner. Terapin \u00e4r alltj\u00e4mt obehaglig, opraktisk och kr\u00e4vande, i synnerhet f\u00f6r \u00e4ldre patienter.<\/p>\n\n\n\n

    Varje behandlingscykel har 28 dagar och under de f\u00f6rsta 7 dagarna av denna period m\u00e5ste patienterna dagligen upps\u00f6ka n\u00e4rmaste infusionsklinik. Sammanlagt tillbringar de runt 30 timmar p\u00e5 kliniken under varje cykel. Injektionerna beh\u00f6ver \u00f6vervakas noggrant och varje g\u00e5ng tar \u00e5terh\u00e4mtningen cirka tv\u00e5 timmar. F\u00f6re och efter varje behandlingscykel med azacitidin ska en komplett blodstatuskontroll g\u00f6ras f\u00f6r att fastst\u00e4lla behandlingssvar och toxicitet. Illam\u00e5ende och kr\u00e4kningar \u00e4r vanliga biverkningar och starka antiemetika administreras rutinm\u00e4ssigt f\u00f6re injektionerna.<\/p>\n\n\n\n

    Denna behandlingsregim \u00e4r inte bara besv\u00e4rlig f\u00f6r patienterna utan ocks\u00e5 dyr f\u00f6r sjukv\u00e5rden j\u00e4mf\u00f6rt med en enda injektion per m\u00e5nad av NEX-18. H\u00e4r finns s\u00e5ledes ett reellt medicinskt behov hos patienter, anh\u00f6riga och v\u00e5rdgivare som inte tillgodoses och som NEX-18 skulle kunna fylla.<\/p>\n\n\n\n\n

    \n \n\n

    (1)<\/strong> Cancer.org<\/a>
    (2)<\/strong>     https:\/\/www.healthline.com\/health\/mds-prognosis<\/a>
    (3)<\/strong> US National Library of Medicine 2017, Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly
    (4)<\/strong> Datamonitor MDS Spotlight Mars 2022<\/p>\n\n\n<\/div>\n\n<\/div><\/section>\n\n

    <\/div>

    injektioner<\/p><\/div>

    \n\n
    \n
    \n

    NEX-18 MINSKAR ANTALET INJEKTIONER FR\u00c5N 1 PER DAG<\/span> sju dagar i str\u00e4ck TILL 1 per m\u00e5nad<\/span><\/h2>\n\n\n\n

    F\u00f6r en behandlingscykel med NEX-18 s\u00e5 ers\u00e4tts de 7 injektionerna med EN injektion med NEX-18 dag 1. Denna f\u00f6renkling av behandlingen ger en stor f\u00f6rdel b\u00e5de f\u00f6r patienter och v\u00e5rdgivare, genom mindre resor samt mer tid till annat f\u00f6r patienten och mindre behov av dyrbara\u00a0resurser\u00a0hos v\u00e5rdgivarna. Detta leder till \u00f6kad livskvalitet\u00a0f\u00f6r patienten och\u00a0l\u00e4gre\u00a0kostnader f\u00f6r v\u00e5rden\/betalare.<\/p>\n<\/div>\n\n\n\n

    \n

    fr\u00e5n 7<\/span> injektioner per m\u00e5nad<\/h3>\n\n\n\n
    \"\"<\/a>
    VIDAZA (5-AZA)<\/figcaption><\/figure>\n\n\n\n

    till 1<\/span> injektion per m\u00e5nad<\/h3>\n\n\n\n
    \"\"<\/a>
    NEX-18\/PHARMASHELL<\/figcaption><\/figure>\n<\/div>\n<\/div>\n\n<\/div><\/section>\n\n
    <\/div>

    MINSKA DEN INITIALA FRIS\u00c4TTNING<\/p><\/div>

    \n\n
    \n
    \n

    Kontrollerad fris\u00e4ttning<\/span>
    F\u00d6R smartare V\u00c5RD<\/h2>\n\n\n\n

    Patienterna uppger (5)<\/sup> att azacitidin i regel ger de sv\u00e5raste biverkningarna i b\u00f6rjan av varje behandlingscykel samt under de f\u00f6rsta tv\u00e5 behandlingscykler som patienten genomg\u00e5r.<\/p>\n<\/div>\n\n\n\n

    \n
    \n\t\n\n
    Biverkningar av AZACITIDINE <\/h5>\n\n\n\n

    Illam\u00e5ende, yrsel, \u00e5ngest, anemi, diarr\u00e9, muskel- och ledv\u00e4rk, neutropeni, infektioner, sepsis, s\u00f6mnrubbningar, njursvikt.<\/p>\n\n\t\t\n<\/div>\n\n<\/div>\n<\/div>\n\n\n\n

    \n
    \n

    Om den initiala \u201dkoncentrationstoppen\u201d vid fris\u00e4ttningen reduceras med hj\u00e4lp av NEX-18 kan det eventuellt minska de akuta biverkningarna fr\u00e5n behandlingen. NEX-18 \u00e4r azacitidin-partiklar som \u00e4r helt inneslutna av en PharmaShell-ytbel\u00e4ggning, som g\u00f6r att en l\u00e5g, kontinuerlig dos av den aktiva substansen fris\u00e4tts under behandlingscykelns g\u00e5ng.<\/p>\n\n\n\n

    Tv\u00e5 olika studier har visat att PharmaShell minskade den initiala fris\u00e4ttningen av testl\u00e4kemedlet indometacin till 1\/28 j\u00e4mf\u00f6rt med den ursprungliga formuleringen, och att l\u00e4kemedlet frisattes i en l\u00e5g och j\u00e4mn takt under loppet av flera veckor (studierna publicerades i de referentgranskade vetenskapliga tidskrifterna European Journal of Pharmaceutics and Biopharmaceutics<\/em> respektive International Journal of Pharmaceutics)<\/em>.<\/p>\n<\/div>\n\n\n\n

    \n

    Hypotes:<\/h4>\n\n\n\n
    \"\"<\/a>
    GraFIK: Funktionsprincip illustrerad av simulerad kontrollerad fris\u00e4ttning med NEX-18 (bl\u00e5 linje) respektive azacitidin (r\u00f6d linje) (6)<\/figcaption><\/figure>\n<\/div>\n<\/div>\n\n<\/div><\/section>\n\n\n\n
    \n \n\n

    (5)<\/strong> https:\/\/mdspatientsupport.org.uk\/latest-news\/mds-patient-stories-2\/<\/a>
    (6)<\/strong> Joel Hellrup, M\u00e5rten Rooth, Emma M\u00e5rtensson, Kalle Sigfridsson, Anders Johansson, 2019. Nanoshells prepared by atomic layer   deposition \u2013 Long acting depots of Indomethacin. European Journal of Pharmaceutics and Biopharmaceutics 140, 60\u201366.   doi:    https:\/\/doi.org\/10.1016\/j.ejpb.2019.04.019<\/a>.<\/p>\n\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    nex 18 F\u00d6R
    BEHANDLING AV mDS (MYELODYSPLASTIC SYNDROME)<\/p>\n

      \n
    1. Vad \u00e4r MDS?<\/a><\/li>\n
    2. NEX-18: Fr\u00e5n en injektion per dag i sju dagar till en injektion i m\u00e5naden<\/a><\/li>\n
    3. NEX-18: Minska den initiala fris\u00e4ttningen<\/a><\/li>\n<\/ol>\n

      \t\t\t<\/p>\n

      Vad \u00e4r<\/p>\n

      VAD \u00c4R MDS?L\u00e4s mer<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-5514","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nNEX-18 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/nex-18\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NEX-18 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"nex 18 F\u00d6R BEHANDLING AV mDS (MYELODYSPLASTIC SYNDROME) Vad \u00e4r MDS?NEX-18: Fr\u00e5n en injektion per dag i sju dagar till en injektion i m\u00e5nadenNEX-18: Minska den initiala fris\u00e4ttningen Vad \u00e4r VAD \u00c4R MDS?L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/nex-18\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-19T08:27:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanexa.com\/wp-content\/uploads\/2021\/10\/syringes-multiple.webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-18\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/nex-18\\\/\",\"name\":\"NEX-18 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-18\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-18\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/syringes-multiple.webp\",\"datePublished\":\"2022-02-21T19:27:54+00:00\",\"dateModified\":\"2022-05-19T08:27:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-18\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/nex-18\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-18\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/syringes-multiple.webp\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/syringes-multiple.webp\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/nex-18\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NEX-18\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NEX-18 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/nex-18\/","og_locale":"sv_SE","og_type":"article","og_title":"NEX-18 - Nanexa AB","og_description":"nex 18 F\u00d6R BEHANDLING AV mDS (MYELODYSPLASTIC SYNDROME) Vad \u00e4r MDS?NEX-18: Fr\u00e5n en injektion per dag i sju dagar till en injektion i m\u00e5nadenNEX-18: Minska den initiala fris\u00e4ttningen Vad \u00e4r VAD \u00c4R MDS?L\u00e4s mer","og_url":"https:\/\/nanexa.com\/nex-18\/","og_site_name":"Nanexa AB","article_modified_time":"2022-05-19T08:27:09+00:00","og_image":[{"url":"https:\/\/nanexa.com\/wp-content\/uploads\/2021\/10\/syringes-multiple.webp","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/nex-18\/","url":"https:\/\/nanexa.com\/nex-18\/","name":"NEX-18 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanexa.com\/nex-18\/#primaryimage"},"image":{"@id":"https:\/\/nanexa.com\/nex-18\/#primaryimage"},"thumbnailUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2021\/10\/syringes-multiple.webp","datePublished":"2022-02-21T19:27:54+00:00","dateModified":"2022-05-19T08:27:09+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/nex-18\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/nex-18\/"]}]},{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/nex-18\/#primaryimage","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2021\/10\/syringes-multiple.webp","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2021\/10\/syringes-multiple.webp"},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/nex-18\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"NEX-18"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/pages\/5514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/comments?post=5514"}],"version-history":[{"count":110,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/pages\/5514\/revisions"}],"predecessor-version":[{"id":6362,"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/pages\/5514\/revisions\/6362"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=5514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}